Tocilizumab (TCZ) is a monoclonal antibody that targets the interleukin-6 receptor, commonly utilized for patients with rheumatoid arthritis (RA) who do not respond adequately to traditional synthetic and biological disease-modifying antirheumatic drugs (DMARDs). The necessity for data from North African populations is evident, as existing literature is limited. This study investigates the effectiveness and safety of TCZ in a real-world setting among patients with refractory RA.
This study is a retrospective cohort analysis conducted at the Department of Rheumatology, Moulay Ismail Hospital in Meknes, Morocco, involving 44 consecutive patients treated with TCZ between April 2019 and January 2024. Patient data including demographic, clinical, and laboratory information, along with treatment details and follow-up data, were gathered from medical records via a standardized electronic form. The primary effectiveness measure was the EULAR response at 6 months, with DAS28-ESR remission defined as scores below 2.6. Safety evaluations monitored complications such as infections, liver enzyme abnormalities, neutropenia, and lipid changes, utilizing the Wilcoxon signed-rank test and chi-square tests for analysis via SPSS version 29.
The cohort primarily consisted of 33 women (75.0%), with a median age of 57 years (ranging from 32 to 82). Patients had a mean RA duration of 12.97±9.1 years and had previously been treated with an average of 2.5±1.8 DMARDs. A significant majority (93.2%) had already undergone at least one biological therapy, which often included multiple tumor necrosis factor (TNF) inhibitors.
At the 6-month follow-up, effectiveness data were available for 34 patients: 67.6% achieved a good EULAR response, 17.6% a moderate response, and 14.7% did not respond. Furthermore, 35.3% of participants were in DAS28-ESR remission. The mean DAS28-ESR score decreased significantly from 5.10±1.18 at baseline to 2.74±1.38 at 6 months, and further to 2.45±1.33 at 12 months. Additionally, the mean dose of prednisone-equivalent treatment reduced from 8.3±7.1 mg/day to 5 mg/day over the same period.
During the study, 22 infectious episodes occurred, including one serious case of purulent pleurisy requiring hospitalization. Five patients (11.4%) temporarily interrupted treatment due to side effects, and one patient (2.3%) permanently discontinued treatment because of hepatotoxicity. Neutropenia was observed in 29.5% of patients, with the mean neutrophil count decreasing from 6.3±3.0 G/L at baseline to 2.6±1.2 G/L at 12 months. Notably, both LDL and HDL cholesterol levels increased during the treatment period.
Analysis of baseline variables revealed that rheumatoid-factor positivity was significantly associated with better EULAR response outcomes (p=0.007). Conversely, a high baseline tender joint count (greater than six) was correlated with lower remission rates (23.5%, p=0.007), as was a borderline significant association with a pain visual analogue scale greater than 65 mm (31.2%, p=0.05).
This investigation into a heavily pretreated cohort indicates that Tocilizumab was linked to a substantial and sustained decrease in disease activity, alongside a manageable safety profile consistent with prior findings. However, a high initial pain and joint burden may signal a reduced chance of achieving remission. The study's small size, retrospective design, incomplete follow-up, and absence of adjusted effect estimates underscore the necessity for cautious interpretation, with reported associations serving primarily as hypotheses for further research.
The authors disclose no competing interests related to this study.
Ethical guidelines were adhered to throughout the study, with necessary approvals obtained from the Research Ethics Committee of the Faculty of Medicine, Euromed University of Fez, Morocco. The committee granted an exemption from full ethics review status, waiving the requirement for individual written consent given the nature of the retrospective analysis. While the anonymized dataset from this study is not publicly available due to institutional restrictions, it can be obtained from the corresponding author upon reasonable request, subject to institutional approval.